METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study Meeting Abstract
| Authors: | Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, S. W.; Han, J. Y.; Kim, C.; Shim, B.; Ricordel, C.; Drilon, A. E.; Pujol, J. L.; Gray, J. E.; Villaruz, L.; Blumenschein, G.; Perez, J.; Modi, D. A.; Kaul, M.; Patel, S.; Hao, Y.; Kim, E.; Magnan, H. |
| Abstract Title: | METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S828 |
| End Page: | S829 |
| Language: | English |
| ACCESSION: | WOS:001326612901604 |
| DOI: | 10.1016/j.annonc.2024.08.1359 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1302P -- Source: Wos |
